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Background: First-line treatment for patients with superficial femoral arterial (SFA) occlusive disease has yet to be
determined. This study compared long-term outcomes between primary SFA stent placement and primary femoral-
popliteal bypass. Periprocedural patient factors were examined to determine their effect on these results.
Methods: All femoral-popliteal bypasses and SFA interventions performed in consecutive patients with symptoms
Rutherford 3 to 6 between 2001 and 2008 were reviewed. Time-dependent outcomes were analyzed using the
Kaplan-Meier method and log-rank test. Cox proportional hazards were performed to determine predictors of graft
patency. Multivariate analysis was completed to identify patient covariates most often associated with the primary
therapy.
Results: A total of 152 limbs in 141 patients (66% male; mean age, 66  22 years) underwent femoral-popliteal bypass,
and 233 limbs in 204 patients (49% male; mean age, 70  11 years) underwent SFA interventions. Four-year primary,
primary-assisted, and secondary patency rates were 69%, 78%, and 83%, respectively, for bypass patients and 66%, 91%,
and 95%, respectively, for SFA interventions. Six-year limb salvage was 80% for bypass vs 92% for stenting (P  .04).
Critical limb ischemia (CLI) and renal insufficiency were predictors of bypass failure. Claudication was a predictor of
success for SFA stenting. Three-year limb salvage rates for CLI patients undergoing surgery and SFA stenting were 83%.
Amputation-free survival at 3 years for CLI patients was 55% for bypass and 59% for SFA interventions. Multivariate
predictors (odds ratios and 95% confidence intervals) of covariates most frequently associated with first-line SFA stenting
were TransAtlantic Inter-Society Consensus II A and B lesions (5.9 [3.4-9.1], P < .001), age >70 years (2.1 [1.4-3.1],
P< .001), and claudication (1.7 [1.1-2.7], P .01). Regarding bypass as first-line therapy, claudicant patients weremore
likely to have nondiabetic status (5.6 [3.3-9.4], P < .001), creatinine <1.8 mg/dL (4.6 [1.5-14.9], P  .01), age <70
years (2.7 [CI, 1.6-8.3], P < .001), and presence of an above-knee popliteal artery target vessel (1.9 [CI, 1.1-3.4] P 
.02).
Conclusion: Indication, patient-specific covariates, and anatomic lesion classification have significant association when
determining surgeon selection of SFA stenting or femoral-popliteal bypass as first-line therapy. Patients with SFA disease
can have comparable long-term results when treatment options are well matched to patient-specific and anatomic


















bRecent reports of improved short-term and midterm
patency with endoluminal stent placement within the su-
perficial femoral artery (SFA) have challenged the historical
dogma that bypass results are categorically superior to
endovascular therapy.1 Many authors have demonstrated
that a variety of patient-specific factors, such as indication
and comorbidities, affect the durability of outcome of SFA
stent placement.1-3 Disease extent and TransAtlantic Inter-
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714ociety Consensus (TASC) II classification are also critical
ot only in predicting successful intervention after endo-
ascular or open surgical therapy in the SFA but also in
nfluencing decisions for the choice of first-line therapy.4,5
A myriad of patient-specific and anatomic variables can
lso affect results of treatment within the SFA, making
herapeutic decision making all the more complex. There
re minimal data comparing bypass vs primary SFA stent
lacement, and as such, determination of optimal patient
election for first-line therapy has not been clearly eluci-
ated. Several series have reported equivalent short-term
nd midterm outcomes for SFA stenting compared with
emoral-popliteal bypass.5,6 Whether the long-term out-
omes of these two therapies are comparable is unknown.
The purpose of this study was to compare outcomes of
onsecutive cases of femoral-popliteal bypass with primary
FA stent placement and to determine long-term results.
e also sought to identify patient characteristics associated
ith selection for primary SFA stent vs femoral-popliteal
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A retrospective review of a prospectively maintained
vascular database at Dartmouth-HitchcockMedical Center
was conducted of consecutive patients with symptoms
Rutherford 3 to 6 undergoing treatment of SFA occlusive
disease between 2001 and 2008. Demographic features,
comorbidities, indications for intervention, indications for
revision, and noninvasive laboratory data were recorded.
Angiographic anatomic data and TASC II classification
were also recorded.
SFA stent intervention. The study included patients
who received primary SFA stenting and had no evidence of
concomitant popliteal or tibial disease. All consecutive pa-
tients underwent primary SFA stent placement with no
adjunctive interventions such as atherectomy, cryoplasty, or
angioplasty alone. Patients had never previously been
treated with endovascular intervention or bypass in the
analyzed limb. All endovascular interventions were per-
formed in an endovascular suite with fixed imaging or in the
operating room with a portable C-arm.
Contralateral femoral access was used in most cases
unless a steep aortic bifurcation or prior abdominal graft
(endovascular or Dacron) precluded this approach. Hepa-
rin (80-100 U/kg) was routinely administered intraproce-
durally with selective protamine usage. Flush SFA occlu-
sions were not considered candidates for SFA stenting.
Lesions were typically crossed with 0.035-inch systems, and
the type of self-expanding nitinol stent used was deter-
mined by operator preference and available inventory.
Most patients were maintained on aspirin and clopi-
dogrel for aminimumof 30 days after the procedure and on
aspirin monotherapy thereafter. Postprocedural surveil-
lance consisted of ankle-brachial index (ABI) measure-
ments at 1 month, 6 months, and annually thereafter.
Among patients with significant tibial calcification and
falsely elevated ABIs, toe pressures were obtained along
with ABIs. Any decrease in ABIs of 0.15 or recurrent
symptoms prompted duplex imaging or arteriography, or
both, to determine stenosis and patency. Primary patency
within the SFA stent patients was defined as freedom from
reintervention or thrombosis.
Femoral-popliteal bypass. All patients who under-
went primary SFA bypass procedures had never previously
undergone an endovascular or surgical intervention. All
bypass patients whose conduit was the ipsilateral leg vein
underwent bypass to the above-knee (AK) or below-knee
(BK) popliteal position. Claudication patients whose by-
pass required a prosthetic conduit received a distal anasto-
mosis only to the AK position. A prosthetic graft was used
selectively to the AK or BK position in patients with a
preoperative indication of critical limb ischemia (CLI).
Surveillance consisted of graft duplex imaging and ABI
measurements at intervals of 1, 3, 6, and 12 months. Toe
pressures were obtained in patients who demonstrated
significant tibial artery incompressibility. Bypass patency
was determined by postoperative duplex imaging and ABI.
Primary patency was defined as freedom from reinterven- fion or thrombosis. Graft failure was defined as bypass
hrombosis, restenosis of 50% of the treated arterial seg-
ent immediately above or below the bypass, intragraft
estenosis 50%, or a decrease in the ABI of 0.15.
tatistical analysis
Main outcome measure and overall analysis. Uni-
ariate comparisons were made between patient character-
stics and loss of primary patency, which was our main
utcome measure. Data were maintained in an Excel
preadsheet (Microsoft Inc, Redmond,Wash) and analyzed
sing STATA 9.2 software (StataCorp, College Station,
ex). Kaplan-Meier survival analysis was performed to as-
ess time-dependent outcomes, and comparisons were
ade with the log-rank test.
Multivariable model to predict graft failure. Cox
roportional hazards regression analysis was used to deter-
ine predictors of failure for the bypass and stenting
roups. The eligibility criterion for evaluation for inclusion
n the model was a univariate analysis value of P  .20.
ackward stepwise regression was used to construct Cox
roportional hazards models, and these models were used
o determine the patient-specific and anatomic variables
ssociated with graft failure. Individual models were con-
tructed for the overall cohort, as well as specific models for
ypass patients and endovascular patients.
Multivariable model to predict choice of interven-
ion. Because the decision for open surgery or endovascu-
ar intervention was not random, we adjusted for con-
ounding factors by the type of revascularization chosen by
he surgeon. To accomplish this, we created a multivariable
ogistic regression model to predict, from patient charac-
eristics, whether the patient would receive open or endo-
ascular revascularization. Patient scores for this model
ere included as a covariate in the Cox proportional haz-
rds models described subsequently to adjust for the possi-
le confounding factors between the choice of revascular-
zation and graft failure, which was our main outcome
easure.
Power analysis. Power analysis was performed with
45 total patients, comprising 141 in bypass group and 204
n the endovascular group. This gave us 69% power to
etect a hazard ratio of 1.5 between the intervention
roups on graft patency at the .05 significance level.
ESULTS
Patient cohort. During the study interval, 152 limbs
n 141 bypass patients and 233 limbs in 204 endovascular
atients were analyzed. Bypass patients were typically
ounger (66 22 vs 70 11 years, P .001) andmale sex
66% vs 55%, P  .03) compared with the primary SFA
tent group. Claudication patients were less likely to un-
ergo bypass than CLI patients (56% vs 46%, P  .07).
ASC D patients underwent more bypass procedures,
hereas TASC B patients had more primary SFA stent
nterventions (Table I). The overall 6-year survival was 64%
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September 2011716 Scali et alA comparison of other common vascular comorbidi-
ties, such as diabetes, chronic renal insufficiency (CRI,
creatinine 1.8 mg/dL), hypertension, or dyslipidemia,
detected no significant difference between groups. To-
bacco use (P  .0001) and statin use (P  .02) was more
common in the bypass patients. Coronary artery disease, as
defined by prior myocardial infarction, was more common
in the SFA stenting group (P .02). The demographic and
clinical data are summarized in Table I.
Bypass. The 152 limbs in 141 patients that underwent
bypass were treated for claudication (46%), rest pain (30%),
and tissue loss (24%). Popliteal bypasses were performed
AK in 55% of limbs and BK in 45%. In the CLI cohort, 45
patients (55%) underwent prosthetic bypass reconstruc-
tion; however, only 12 (15%) of these patients received an
anastomosis to the BK position. An AK anastomosis was
created in 28 patients (39%) with a preoperative indication
of claudication who underwent femoral-popliteal bypass
reconstruction with a prosthetic graft. The conduit was
great saphenous vein in 54% of bypasses and expanded
polytetrafluoroethylene in 46%. Concomitant iliofemoral
endarterectomy was performed in 31% of limbs.
Patency and reintervention. Four-year primary, pri-
mary-assisted, and secondary patency rates (95% confidence
interval [CI]) were 69% (79%-99%), 78% (68%-88%) and
83% (74%-92%), respectively, for bypass patients (Fig 1).
The 6-year primary patency rate was 49% (35%-63%) for AK
vs 75% (59%-81%) for BK popliteal bypass. The 6-year
primary patency rates were 67% (56%-78%) for great saphe-
nous vein vs 32% (17%-48%) for prosthetic bypass. The
Table I. Demographics of patients undergoing
revascularization for superficial femoral artery (SFA)
occlusive disease
Variablea Bypass SFA stent P
Total patients 141 204
Total limbs 152 233
Age, years 66  22 (38-87) 70  11 (37-99) .0013
Male sex 101 (66) 129 (55) .0302
Indication
Claudication 70 (46) 130 (56) .0773
CLI 82 (54) 103 (44)
Diabetes 64 (42) 105 (45) .5686
Creatinine 1.8
mg/dL 17 (11) 21 (9) .5594
Hypertension 115 (76) 192 (82) .0897
Hyperlipidemia 105 (69) 160 (69) .9813
Statin use 101 (66) 106 (55) .0197
Smoking 75 (49) 70 (30) .0001
CAD 53 (35) 110 (47) .0165
TASC lesion .0001
A 3 (2) 41 (18)
B 50 (33) 145 (62)
C 33 (22) 32 (14)
D 66 (43) 15 (6)
CAD, Coronary artery disease; CLI, critical limb ischemia; TASC, TransAt-
lantic Inter-Society Consensus.
aData are shown as number (%) or mean  standard deviation (range).overall 6-year limb salvage rate for all bypass patients was d0% (81%-95%). Only 4% of limbs in CLI patients with rest
ain or tissue loss required major amputation, and minor
mputations were performed in 8% of limbs.
Reintervention was required in 24% of bypass patients.
ithin that group, 72% were open reintervention (throm-
ectomy, vein patch, graft removal), 22% were endovascu-
ar (angioplasty, stent, thrombolysis), and 6% comprised
epair of lymph leak and wound debridement. The overall
omplication rate was 21%, consisting of 20% bleeding/
ematoma, 3% emergency reoperation, 3% wound infec-
ion, 14% pneumonia, 1% lymph leak, 2% urinary tract
nfection, 1% respiratory failure, and 9.8% transient isch-
mic attack (Table II).
With regard to the SFA stent cohort, 4-year primary,
rimary-assisted, and secondary patency rates (95% CI)
ere 66% (56%-76%), 91% (84%-98%), and 95% (90%-99%)
or SFA stent interventions. The 6-year limb salvage rate
as 92% in the endovascular cohort vs 80% (log-rank, P 
04); however, a higher proportion of these patients had
laudication (Fig 1). The reintervention rate was 14%.
ithin that group, 52% had open interventions (bypass,
hrombectomy, endarterectomy) and 48% had endovascu-
ar reintervention (angioplasty, stenting, thrombolysis).
No major amputations were performed on limbs un-
ergoing SFA intervention, and minor amputation was
equired in 4% of extremities. The complication rate in this
ohort was 2.1%, comprising 0.8% bleeding/hematoma,
.4% emergency operation, and 0.4% urinary tract infection
Table II).
Predictors of patency. Cox regression analysis was
sed to determine predictors of failure for the entire cohort
f patients. Poor runoff, renal insufficiency, and CLI were
redictors of failure for any intervention performed in this
atient cohort. The type of intervention, SFA stenting or
emoral-popliteal bypass, was not a predictor of failure
Table III).
To further look at predictors of patency, we used a Cox
egression analysis for the bypass and stent groups indepen-
ently. Predictors of failure of bypass grafts were decreased
enal function, poor outflow, and lack of statin therapy.
redictors of failure for the stent group were indication,
uch that CLI patients had worse patency compared with
laudicant patients. Previously reported predictors of SFA
r bypass failure, such as TASC classification or diabetes,
id not predict patency (Table III). Because indication was
etermined to be an important predictor of patency, and
he patients treated for claudication vs CLI are different, we
tratified our results by the diagnosis of claudication or
LI.
Outcomes for claudication cohort. The primary, pri-
ary-assisted, and secondary patencies were similar in the
ypass and SFA stent groups. Specifically, the primary
atency rate (95% CI) at 3 years was 78% (61%-95%) for
laudicant patients receiving femoral-popliteal bypass vs
9% (70%-99%) for primary SFA stenting (Fig 2). Limb
alvage was 100% for bypass as well as SFA stents. The
-year amputation-free survival (AFS) was 92% in the clau-
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Volume 54, Number 3 Scali et al 717group. No outcomes of primary patency, limb salvage, or
amputation-free survival were significantly different be-
tween intervention groups for claudicant patients by log-
rank analysis. No predictors of long-term patency were
identified.
Outcomes for the CLI cohort. The CLI patients
who underwent primary bypass or SFA stent placement
had comparable primary, primary-assisted, and second-
ary patencies. Primary patency (95% CI) at 3 years for
CLI patients was 67% (59%-85%) for bypass surgery and
43% (23%-63%) for SFA stenting. No significant differ-
ences were found when limb salvage or amputation-free
survival was compared by log-rank analysis. Limb salvage
for bypass surgery and SFA stenting for CLI patients was
83% for both at 3 years (Fig 3, A). More importantly,
bypass and primary stent patients with CLI had similar
Fig 1. Overall, cumulative 4-year patency is shown
superficial femoral artery (SFA) stent placement cohorts
popliteal bypass was 0.05 at 4 years. The femoral-poplitea
Right, The standard error for survival curves in the prima
number at risk was 233 at the start and 58 at 4 years. CI
Table II. Preoperative complications
Variable Bypass (%) SFA stent (%) P
Emergency re-op 0.0 0.4 .45
Bleeding 3.3 0.8 .09
Urinary tract infection 0.7 0.4 .70
Wound infection 13.8 0.0 .0001
Pneumonia 1.3 0.0 .10
Transient ischemic attack 0.7 0.0 .23
Lymph leak 2.0 0.0 .04
Respiratory failure 0.7 0.0 .23
Death 0.0 0.8 .27
Total 21.0 2.1 .0001
SFA, Superficial femoral artery.outstanding results for AFS. AFS at 3 years was 55% for fiypass patients compared with 59% for the primary SFA
tent patients (Fig 3, B).
Selection of revascularization strategy among pa-
ients with claudication. Because the overall results of the
rimary SFA stent and bypass experience in this series are
mong some of the best reported outcomes in the literature
nd indication was a predictor of patency, multiple logistic
egression models were used to better understand patient
election bias that may have led to these data. Logistic
egression was performed to determine characteristics of
laudication patients that were associated with bypass being
hosen compared with endovascular therapy. Nondiabetic
tatus, age 70 years, normal renal function (glomerular
e (left) femoral-popliteal bypass and (right) primary
t, Standard error for all survival curves for the femoral-
ass number at risk was 152 at the start and 36 at 4 years.
A stent group was 0.06 at 4 years. The primary SFA stent
fidence interval.
able III. Predictors of patency by Cox proportional
azard models
ariable HR (95% CI) P
verall cohort
One-vessel outflow 53.311 (4.938-575.497) .0011
Creatinine 1.8 mg/dL 1.890 (1.059-3.378) .0316
Critical limb ischemia 2.976 (1.375-6.410) .0133
Bypass vs stent 1.079 (0.596-1.947) .7997
rocedure-specific model
ypass
One-vessel outflow 47.609 (4.077-555.952) .0021
Creatinine 1.8 mg/dL 3.012 (1.199-7.576) .0189
Not taking statin 2.573 (1.243-5.326) .0109
ndovascular
Critical limb ischemia 10.753 (3.831-30.030) .0001
I, Confidence interval; HR, hazard ratio.for th
. Lef
l byp
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September 2011718 Scali et alAK target were covariates associated with surgeon choice
of bypass as first-line therapy in the claudication cohort.
Hence, claudicant patients who underwent bypass were
more likely to be younger and healthier with a good
target for bypass (Table IV).
Logistic regression was then done to determine char-
acteristics of patients given the option of primary stenting
by the surgeon. Factors that influenced surgical decisions
about the likelihood of receiving SFA stenting as a first-line
therapy were the presence of TASC A and B lesions (odds
ratio [OR] 5.9; 95% CI, 3.9-9.1; P .001), age70 years
(OR, 2.1; 95% CI, 1.4-3.1; P  .001), and claudication as
a preoperative indication (OR, 1.7; 95% CI, 1.1-2.7; P 
.01; Table IV). Therefore, stented patients were more likely
older claudicant patients with limited SFA disease.
DISCUSSION
These results represent one of the largest and longest
follow-ups to date for primary SFA stent vs bypass out-
comes. Because the results for primary SFA stenting and
bypass for claudicant patients are comparable, when pa-
tients are chosen in a similar fashion, a less-invasive inter-
vention, such as primary SFA stent placement, should be
offered for first-line therapy in this patient cohort. In a
similar manor, CLI patients can have equivalent outcomes
for primary SFA stent placement vs femoral-popliteal by-
pass as long as age, renal function, diabetic status, and
presence of a BK popliteal target are considered in the
treatment algorithm. This conclusion is further supported
by the Cox regression analysis to determine predictors of
failure for the entire cohort. Choice of type of intervention did
not predict failure; therefore, if patient selection is appropriate,
either procedure to treat patients with femoral-popliteal dis-
ease should lead to equivocal results.
Owing to the durable and comparable outcomes be-
Fig 2. Cumulative 3-year patency is shown for the claudicant
patients undergoing femoral-popliteal bypass and primary superfi-
cial femoral artery (SFA) stenting. Number of claudicant patients
with femoral-popliteal bypass at risk was 70 at the start and 22 at 3
years. The standard error was 0.09 at 3 years. Number of claudicant
patients with primary SFA stent at risk was 130 at the start and was
41 at 3 years. The standard error was 0.089 at 3 years.tween the two treatment modalities, regardless of indica- bion, our group sought to understand the clear selection
ias that must be present when determining which patients
eceive the given treatment. After analyzing the anatomic
nd comorbid attributes of the various CLI and claudicant
ohorts, we were not surprised to find that patients with
ASC A or B lesions, older patients (age 70 years), and
laudicant patients were more likely to undergo primary
FA stent placement (Table IV).
Contemporary practice management of the claudicant
atient should still center on modification of risk factors.
nvariably, however, a small cohort of patients will be
isabled despite these interventions.7 Once committed to
reatment, one must weigh the attendant risks and benefits
f invasive intervention. Prudence would dictate choosing a
odality that has the greatest durability with the least
mount of morbidity.8 Thus, it was not surprising to find
hat in our practice, open operations for claudicant patients
ypically occurred in those who were younger, had an AK
opliteal artery target, and were less likely to have acceler-
ted disease progression over time due to a nondiabetic
tatus.9 Therefore, claudicant patients who were young and
ad limited comorbidities were more likely to have better
ong-term survival. Subsequently, given the historically
ore durable procedure of SFA bypass, this was more
requently offered as the primary intervention.
The converse analysis is that CLI patients offered femoral-
opliteal bypass as a first-line option were more often older,
ad renal insufficiency, were diabetic, and had typically only a
K popliteal target. Absence of an AK popliteal target invari-
bly heralds the presence of more complicated TASC C or D
esions, which have been shown in multiple series to have
uperior outcomeswith bypass.6,9,10An“endo-first” option is
esirable for older patients with multiple comorbidities; how-
ver, they frequently have associated comorbidities, such as
iabetes or renal insufficiency, that lead to more advanced
rterial occlusive disease. This often predicts poorer outcomes
ith a percutaneous intervention, particularly in patients with
issue loss.11
Although this series compares well with previous large-
cale series for CLI patients, it is important to note that
quivalent limb salvage rates of 83% at 3 years were
chieved in CLI patients undergoing primary bypass or SFA
tent placement.3 In addition, 3-year AFS was no different
n the CLI cohort of patients when the two therapies were
ompared (55% bypass vs 59% stent). None of the study
atients had a popliteal intervention, so when clinicians are
aced with the decision of which first-line therapy to offer,
onsideration of the anatomic and physiologic cost of fail-
re, need for salvage or bail-out revascularization, and
verall medical risk stratification of the patient affect the
linical selection bias.
A limitation of contemporary endovascular practice is
hat the conduit status is often unknown before clinical
ecision analysis that is made to determine which first-line
herapy to offer. We contend that in patients with usable
utologous conduit and CLI, particularly those with tissue
oss, primary SFA bypass should be offered. Bypass should




























JOURNAL OF VASCULAR SURGERY
Volume 54, Number 3 Scali et al 719should be weighed, and the threshold for this therapy over
SFA stenting should be lowered in patients with CRI and
diabetes given the effect of these comorbidities on durabil-
ity of endovascular intervention.12,13
Another important finding in this series, in contrast to
previously published data, is that TASC II classification was
not a predictor of primary patency after primary SFA stent
placement. Of the patients in this study, 55% of the bypass
cohort and 76% of the endovascular cohort were TASC B
or C patients. Previous reports of decision analysis model-
ing regarding the treatment of these lesions have advocated
a first-line angioplasty with stenting approach for disabling
claudication patients. However, low-risk TASC C patients
likely gain greater benefit from a great saphenous vein
bypass.14 Lesion morphology (stenosis vs occlusion) can
affect outcome, and several reports identify lesion length
with outcome in the historical and contemporary vascular
Fig 3. A,Limb salvage and (B) amputation-free 3-year s
superficial femoral artery (SFA) stent groups in patien
femoral-popliteal bypass, number at risk was 82 at the s
amputation-free survival, the number was 82 at risk to sta
limb salvage after primary SFA intervention, the numbe
standard error was 0.088 at 3 years. For amputation-free
The standard error was 0.089 at 3 years. CI, Confidence
Table IV. Characteristics of claudication patients
receiving femoral-popliteal bypass
Covariate OR (95% CI) P
Nondiabetic 5.6 (3.3-9.4) .001
Age 70 years 2.7 (1.6-8.3) .001
Creatinine 1.8 mg/dL 4.6 (1.5-14.9) .01
Above-knee target 1.9 (1.1-3.4) .02
CI, Confidence interval; OR, odds ratio.surgical literature.15,16 Consensus guidelines have been tublished on the “best practice” treatment of SFA occlu-
ive disease; however, many clinicians are influenced by
dditional patient-specific comorbidities when deriving so-
utions for intervention.4
This contemporary series has demonstrated that a num-
er of clinical factors, both comorbid and anatomic, are
ore frequently associated with a given treatment strategy.
e contend that these factors likely led to surgeon bias that
ltimately resulted in the selected revascularization strat-
gy. One important limitation, as mentioned previously, is
he patient’s preintervention conduit status. A patient who
acks an adequate conduit for lower extremity arterial re-
onstruction is more likely to undergo an endovascular
ntervention.12 This analysis did not capture this informa-
ion; however, it likely reflects a real-world experience
here patients present with complaints of lifestyle-limiting
laudication, rest pain, or tissue loss and invariably undergo
iagnostic arteriography. Once in the interventional suite,
he vascular surgeon is left with the knowledge of the
atient’s comorbid status and TASC II classification to
ltimately decide on the best initial therapy.
A variety of authors have reported SFA stent outcomes
n medically high-risk patient cohorts and patients who are
unctionally impaired or at extremes of age.10,17 These
atients are likely to be unfit for bypass. However, deter-
ining which factors are most important when deciding an
ntervention is the key issue because there are historical
eports of good outcomes for infrainguinal revasculariza-
al are shown for the femoral-popliteal bypass and primary
h critical limb ischemia (CLI). For limb salvage after
nd 22 at 3 years, and the standard error was .088. For
24 at 3 years, and the the standard error was 0.097. For
isk was 103 at the start and 35 at 3 years was 35. The
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disease that stratify them into a high-risk cohort for con-
ventional open infrainguinal arterial reconstruction.19
Multiple series have identified diabetes, age80 years, and
renal failure as independent physiologic predictors of bad
outcomes for both endovascular and open surgical revascu-
larization.13,20,21 In our series for the SFA stent cohort, we
noted overall similar outcomes compared with bypass, and
the only predictor of poor patency was indication. High-
risk patients or patients with significant comorbidities who
had claudication were given SFA stenting as a primary
option. One would consider all CLI patients to be medi-
cally high risk because CLI could be considered a surrogate
for worse coronary artery disease and cerebrovascular dis-
ease. That being said, CLI patients given the primary
option of SFA stenting were those whose options for bypass
were still available if SFA stenting failed. These reported
experiences, plus the TASC II recommendations, are likely
to be weighed differentially in the clinician’s mind when
attempting to navigate a clinical treatment algorithm for
femoral-popliteal occlusive disease.
Although these data rival or exceed reported out-
comes for primary SFA stenting vs bypass, the study has
several limitations. This was not a randomized trial di-
rectly comparing primary SFA stent placement with
femoral-popliteal bypass. A future goal would be to
conduct such a trial in an attempt to better determine
and more directly compare the two treatment strategies.
A propensity score would have been a better method to
compare the subgroups; however, the numbers were too
small to perform this analysis.
Another limitation of our work is that the unit of
analysis in our study was the procedure, not the patient, and
some patients had procedures on both limbs, including 11
patients (7% of the total) who had a bypass procedure on
their contralateral limb and 29 patients (12% of the total)
who underwent stent placement in their contralateral limb.
Although these patients represent a small proportion of all
patients and were not systematically different than the
population undergoing unilateral procedures, we cannot be
sure that these “events” were truly independent of each
other. Our observed standard errors do not take into ac-
count the possibility of within-patient correlation, al-
though given the similarity of these populations, it seems
unlikely these would change the main effects of our find-
ings.
Better quantification of the claudication outcomes,
such as walking distance rather than patency and limb
salvage, would have been a more optimal comparative end
point. In addition, outcome measures, such as major ad-
verse limb events, will likely be more useful when determin-
ing the efficacy of the treatment options given to patients.
Nonetheless, this report represents some of the longest-
term follow-up and outcome reporting in a contemporary
series of consecutive patients treated for superficial femoral
arterial occlusive disease.
1ONCLUSIONS
Understanding the different effect of the various phys-
ologic and anatomic factors that can affect outcomes of
emoral-popliteal revascularization is paramount to achiev-
ng optimal outcomes. When patient-specific and anatomic
haracteristics are matched appropriately, equivalent out-
omes can be achieved between endovascular and open
urgical revascularization of the SFA regardless of indica-
ion or TASC classification.
UTHOR CONTRIBUTIONS
onception and design: ER, SS, PG, AB
nalysis and interpretation: ER, SS, DS, DW, PG, RP
ata collection: ER, AB, PG
riting the article: SS, ER, DS, DW
ritical revision of the article: SS, ER, AB,DS,DW, PG, RP
inal approval of the article: ER, SS, AB, DS, DW, PG, RP




1. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al.
Balloon angioplasty versus implantation of nitinol stents in the superfi-
cial femoral artery. N Engl J Med 2006;354:1879-88.
2. Nakagawa Y, Yajima J, Oikawa Y, Ogasawara K, Kirigaya H, Nagashima
K, et al. Clinical outcomes after percutaneous peripheral intervention
for chronic total occlusion of superficial femoral arteries: comparison
between self-expandable nitinol stent and stainless steel stent. J Cardiol
2009;53:417-21.
3. Surowiec SM, Shirley EW, Rhodes JM, Illig KA, Shortell CK, Lee DE,
et al. Percutaneous angioplasty and stenting of the superficial femoral
artery. J Vasc Surg 2005;41:269-78.
4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA. Fowkes
FGR and on behalf of the TASC II Working Group. Inter-Society
Consensus for the Management of peripheral Arterial Disease (TASC
II). J Vasc Surg 2007;45:S5-S67.
5. Dosluoglu HH, Cherr GS, Lall P, Harris LM, Dryjski ML. Stenting vs
above knee polytetrafluoroethylene bypass for TransAtlantic Inter-
Society Consensus-II C and D superficial femoral artery disease. J Vasc
Surg 2008;48:1166-74.
6. Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz
SG, et al. Primary stenting of the superficial femoral and popliteal artery.
J Vasc Surg 2009;50:542-7.
7. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary
patency of long-segment self-expanding nitinol stents in the femoro-
popliteal arteries. J Endovasc Ther 2005;12:6-12.
8. Almahameed A, Bhatt DL. Contemporary management of peripheral
arterial disease: III. Endovascular and surgical management. Cleve Clin
J Med 2006;73(suppl 4):S45-51.
9. Bakken AM Palchik E, Rhodes JM, Saad WE, Davies MG. Impact of
diabetes mellitus on outcomes of superficial femoral artery endoluminal
interventions. J Vasc Surg 2007;46:946-58.
0. Banerjee S, Brilakis ES, Das TS, Lichtenwalter CS. Treatment of Com-
plex Superficial Femoral Artery Lesions with PolarCath cryoplasty. Am J
Cardiol 2009;104:447-9.
1. Setacci C, Chisci E, de Donato G, Setacci F, Iacoponi F, Galzerano G,
et al. Subintimal angioplasty with the aid of a re-entry device for TASC
C and D lesions of the SFA. Eur J Vasc Endovasc Surg 2009;38:76-87.
2. Ihnat DM, Duong ST, Taylor ZC, Leon LR, Mills JL Sr, et al.
Contemporary outcomes after superficial femoral artery angioplasty and
stenting: the influence of TASC classification and runoff score. J Vasc
Surg 2008;47:967-74.3. Florian D, Galimanis A, Husmann M, Schmidli J, Baumgartner I.




JOURNAL OF VASCULAR SURGERY
Volume 54, Number 3 Scali et al 721ischemia: Influence of diabetes mellitus on clinical outcome. J Vasc Surg
2007;45:751-61.
14. Nolan B, Finlayson S, Tosteson A, Powell R, Cronenwett J. The
treatment of disabling intermittent claudication in patients with super-
ficial femoral artery occlusive disease-Decision analysis. J Vasc Surg
2007;45:1179-84.
15. Jørgensen B, Tønnesen KH, Holstein P. Late hemodynamic failure
following percutaneous transluminal angioplasty for long and multifo-
cal femoropopliteal stenoses.. Cardiovasc Intervent Radiol 1991;14:
290-2.
16. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et
al. Primary patency of femoropopliteal arteries treated with nitinol
versus stainless steel self-expanding stents: propensity score-adjusted
analysis. Radiology 2004;232:516-21.
17. Nishibe T, Kondo K, Nishibe M, Muto A, Dardik A. Stent placement8. Hnath J, Roddy SP, Darling RC 3rd, Paty PS, Taggert JB, Mehta M.
Comparative results of open lower extremity revascularization in nona-
genarians. J Vasc Surg 2009;49:1463-4.
9. Ohta T, Hosaka M, Ishibashi H, Sugimoto I, Mihara E, Hida K, et al.
Limb salvage and survival rates among elderly patients with advanced
limb ischemia. Surg Today 1998;28:151-61.
0. Vainio E, Salenius JP, Lepäntalo M, Luther M, Ylonen K. Endovascular
surgery for chronic limb ischemia. Factors predicting immediate out-
come on the basis of a nationwide vascular registry. Ann Chir Gynaecol
2001;90:86-91.
1. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari
CM, et al. A decade of experience with infrainguinal revascularization in
a dialysis-dependent patient population. J Vasc Surg 2002;36:969-74.for superficial femoral arterial occlusive disease in high-risk patients:
preliminary results. Surg Today 2009;39:21-6. Submitted Apr 1, 2010; accepted Mar 3, 2011.
CME Credit Now Available to JVS Readers
Readers can now obtain CME credits by reading selected articles and correctly answering multiple choice questions
on the Journal website (www.jvascsurg.org). Four articles are identified in the Table of Contents of each issue and 2
questions for each are posted on the website. After correctly answering the 8 questions, readers will be awarded 2
hours of Category I CME credit.
